Simultaneous and Longitudinal Comparison of Interferon Gamma Release Assay Data from Health Care Workers in Japan

Tomoshige Matsumoto¹, Yukio Hirayama¹, Yuka Hisamitsu¹, Megumi Fukumura¹, Akemi Hirata¹, Kumi Tanaka¹, Masashi Kurokawa¹, Yoshitaka Tamura¹, Hisako Yoshida¹, Takayuki Nagai¹, Ichiro Kawase¹, Koichi Suzuki¹ and Yoshihiko Hoshino²*

¹Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan
²National Institute of Infectious Diseases, Japan

Abstract

Background: Tuberculosis is one of the serious occupational diseases among health care workers, especially those who work with patients suffering from respiratory disorders. It is important to assess latent tuberculosis infection status in such workers using interferon-γ release assays, including QuantiFERON-TB Gold and its successor, the QuantiFERON-TB Gold in-Tube test. Although the relative efficacies of these two methods have been evaluated in patients with tuberculosis, data from health care workers in Japan have not been extensively examined.

Purpose: In the present study, we examined the utilities of the QuantiFERON-TB Gold and QuantiFERON-TB Gold in-Tube tests to detect latent tuberculosis infections in staff working in a respiratory disease hospital in Japan. We also longitudinally compared data from these subjects obtained using the QuantiFERON-TB Gold assay.

Methods: We collected blood samples from 120 staff members and performed both the QuantiFERON-TB Gold and QuantiFERON-TB Gold in-Tube assays. A total of 58 subjects had previously been tested 5 years prior using the QuantiFERON-TB Gold assay, and we compared these data with our more recent information.

Results: The QuantiFERON-TB Gold in-Tube test tended to yield higher test values than did the QuantiFERON-TB Gold test, suggesting that the former test may be more sensitive when used to detect latent tuberculosis infection. In both tests, the results differed in 32 instances (26.7%), associated with significant difference (p=0.001, χ²=0.55). In 94 subjects with negative QuantiFERON-TB Gold test results, 16 (17.0%) were intermediate and 11 (11.7%) positive by QuantiFERON-TB Gold in-Tube test. The longitudinal comparison confirmed this suggestion. The number of subjects rated “intermediate” in terms of tuberculosis status differed, with statistical significance, when the two datasets were compared.

Conclusion: Health care workers should be screened for possible tuberculosis infections using the QuantiFERON-TB Gold in-Tube test, which is more sensitive than the QuantiFERON-TB Gold test.

Keywords: Interferon-gamma release Assay; Latent tuberculosis infection; Health care workers

Abbreviations: BCG: Bacillus Calmette-Guérin; CFP-10: Culture Filtrate Protein; ESAT-6: Early Secreted Antigenic Target; HCW: Health Care Workers; IFN-γ: Interferon-Gamma; IGRA: Interferon-Gamma Release Assay; LTBI: Latent Tuberculosis Infection; Mtb: Mycobacterium Tuberculosis; NTM: Non-Tuberculosis Mycobacteria; PBMC: Peripheral Blood Mononuclear Cells; QFT-G: Quantiferon-TB Gold; QFT-GIT: Quantiferon-TB Gold In-Tube; TB: Tuberculosis; TST: Tuberculin Skin Test

Introduction

The incidence of tuberculosis (TB) in Japan is less than 20 per 100,000 population and is continuing to decline. However, TB remains a major occupational disease of health care workers (HCW) [1,2]. Several reports have shown that HCW were at several-fold higher risk for TB than the general population [3-6]. One practical way to control TB is routine screening of HCW for latent tuberculosis infections (LTBIs) and administration of chemoprophylaxis to HCW suspected to have LTBI. Therefore, evaluation of Mycobacterium tuberculosis (Mtb) infective status is crucial in HCW working in hospitals dedicated to TB patients [2,7,8]. In such contexts, screening of HCW should be routine and data should be evaluated longitudinally [2,9].

Recently, methods detecting Mycobacterium tuberculosis (Mtb)-specific antigens have been developed. The target antigens include culture filtrate protein 10 kD (CFP-10), early secreted antigenic target 6 kD (ESAT-6), and TB7.7 [10-12]. The QuantiFERON-TB Gold (QFT-G) test uses CFP-10 and ESAT-6, whereas its successor, the QuantiFERON-TB Gold in-Tube test (QFT-GIT), additionally uses TB7.7 [13-15]. The results of the two assays cannot be directly compared, because not only do the stimulating antigens used vary, but some differences are evident in the methods used to stimulate lymphocytes. Thus, in the QFT-G tests, lymphocytes are separately stimulated by a mixture of CFP-10 and ESAT-6, and TB7.7 is commenced just after blood is drawn for the QFT-GIT assay [16,18-21]. Several investigators have reported that the sensitivity of QFT-GIT was higher than that of QFT-G, but that the specificity values were similar [10,11,20,21]. One issue that must be considered is the intermediate results introduced in some countries including Japan, but not most developed countries [20]. In Japan, an intermediate result
(0.10 IU/ml ≤ IFN-γ level <0.35 IU/ml) is recognized but the definition of intermediate varies among countries [17,19]. One study concluded that intermediate results were more frequent by QFT-GIT than by QFT-G [20].

In the present study, we compared simultaneously derived QFT-G and QFT-GIT assay data from HCW in Japan. We also compared our results with those of QFT-G tests performed five years prior in some subjects.

Subjects and Methods

Study design

This cross-sectional study involved 120 HCW of the Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan. No subject had any underlying illnesses such as acute infection, autoimmune disorder, or any other chronic disease. No subject had an abnormal chest X-ray. The study protocol was approved by the Review Board of the Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, and written informed consent was obtained from all participants.

QFT-G and QFT-GIT assays

The QFT-G and QFT-GIT assays were performed following the instructions of the manufacturer (Cellestis Limited, Carnegie, Australia). Blood samples were collected by normal phlebotomy into both evacuated 4 ml sterile sodium heparin tubes for QFT-G assay and into three 1 ml-volume QFT-GIT blood collection tubes [17-19]. When QFT-G tests were run, incubation with Mtb-specific antigens was initiated within 12 h of blood collection. After incubation for 24 h at 37°C, samples were centrifuged at approximately 500 g for 10 min to facilitate plasma collection. Plasma samples were stored at -70°C prior to conduct of ELISA detecting IFN-γ.

QFT ELISA assay

The concentrations of IFN-γ in plasma samples were determined via ELISA according to the manufacturer’s protocol. All ELISAs were performed by the same trained staff. QFT-G and QFT-GIT test responses were automatically calculated using QFT-G ELISA Analysis software (Cellestis Limited) after input of ELISA plate optical density values. QFT-G and QFT-GIT test data were interpreted as suggested by the manufacturer. An IFN-γ response to Mtb-specific antigens that was at least 0.35 IU/ml and greater than the nil control value was considered positive. Samples with 0.10 ≤ IFN-γ level <0.35 IU/ml were regarded as intermediate, according to guidelines of Committee for Prevention of the Japanese Society of Tuberculosis [17,19]. Mitogen stimulation was used to positively control the quality of both blood samples and laboratory technique. If a sample IFN-γ value was <0.35 IU/ml when the positive control value (upon mitogen stimulation) was ≥ 0.5 IU/ml, the test result was considered to be negative.

Data analyses

The extent of agreement between data yielded by the two tests was evaluated using the McNemar approach, and agreement was expressed in terms of both a kappa coefficient and the level of overall agreement (the proportions of samples yielding positive or negative results in both tests). Non-parametric statistics (Wilcoxon’s ranked sign test and Spearman’s ranked correlation coefficient) were employed when the means of IFN-γ measurements obtained using either method were compared. A difference associated with a p value <0.05 was considered to be statistically significant.

Results

Comparison of QFT-G and QFT-GIT assay data from 120 Japanese HCW

When comparing QFT-G and QFT-GIT assay data from 120 blood samples obtained at the same time, QFT-GIT yielded higher IFN-γ levels than did QFT-G in most samples (Figure 1). However, the results (positive, intermediate, or negative) differed in 32 instances (26.7%), associated with a significant difference in the results of the two assays (p <0.001 by Wilcoxon’s ranked sign test; k =0.5503 by weighted value).

Thus, in 94 subjects with negative QFT-G test results, 16 (17.0%) were intermediate and 11 (11.7%) positive by QFT-GIT (Table 1); only 67 subjects (71.2%) were negative on both tests. Similarly, of eight subjects diagnosed as intermediate by the QFT-G test, two (25%) were positive by QFT-GIT and only four (50%) yielded the same intermediate result. Moreover, two subjects (25%) scored as intermediate by the QFT-G test were negative by QFT-GIT, probably reflecting the indeterminacy of intermediate results. Seventeen of 18 (94%) subjects positive by QFT-G were also positive by QFT-GIT; although the IFN-γ levels yielded by the latter test were higher (Figure 1). However, one of these 18 (6%) subjects was diagnosed as intermediate by QFT-GIT; although the IFN-γ level measured by QFT-G was just above the cut-off level > 0.35 IU/ml (±). IFN-γ levels falling in the shaded area (0.1 IU/ml ≤ IFN-γ level <0.35 IU/ml) are regarded as intermediate in Japan. An arrow indicates one case that yielded an intermediate QFT-GIT test result, but who was positive by QFT-G, although the IFN-γ level was just above the (lower) positive cut-off value in the latter test.

![Figure 1: Comparison of two simultaneous IGRAs. Blood samples from 120 HCW were simultaneously examined using two different IGRAs. IFN-γ concentrations are shown. In both assays, a level of IFN-γ less than 0.1 IU/ml constituted a negative result. IFN-γ levels falling in the shaded area (0.1 IU/ml ≤ IFN-γ level <0.35 IU/ml) are regarded as intermediate in Japan. An arrow indicates one case that yielded an intermediate QFT-GIT test result, but who was positive by QFT-G, although the IFN-γ level was just above the (lower) positive cut-off value in the latter test.](image_url)

| QFT-G | QFT-GIT | Total |
|-------|----------|-------|
| (-)   | 67       | 11    | 94    |
| (±)   | 2 (17.0%)| (±)   | 4 (11.7%) | (100%) |
| (+)   | 0 (25%)  | (+)   | 1 (25%)  | (100%) |
|       | 1 (0%)   |       | 17      | (94%)  |
| Total | 69       | 21    | 120    |

Table 1: Comparison of simultaneous QFT-G and QFT-GIT assays.
Of 38 previously negative subjects, 10 (26.3%) were of intermediate status and 1 (2.6%) was positive (0.84 IU/ml); this positive case was negative upon recent QFT-G testing. This subject was diagnosed as intermediate upon recent QFT-GIT testing. Of nine previously intermediate cases, four (44.4%) were positive and the others remained intermediate on recent QFT-GIT testing. Nine of 11 previously positive QFT-G cases remained positive, but two (18.2%) became intermediate upon recent QFT-GIT testing.

**Discussion**

In the present study, we simultaneously compared QFT-G and QFT-GIT test results and also performed a longitudinal comparison of recent data with earlier QFT-G results obtained 5 years prior, because such a comparison should be helpful in terms of early diagnosis of LTBI in HCW, especially staff of dedicated tuberculosis wards. We confirmed that the QFT-GIT test was more sensitive than the QFT-G test when used to screen HCW, similar to the results of a previous study in TB patients [20]. However, discrepancies were evident between the results of recent QFT-GIT and QFT-G tests and also when these data were compared with QFT-G results obtained 5 years prior. Differences between the results of the QFT-GIT and QFT-G tests may be attributable to differences in the antigens used to stimulate interferon secretion; such antigens may exert synergistic effects.

Differences between recent test results and older data may be attributable to functional regression of Mtb-specific T lymphocytes [22]. In BCG-vaccinated newborns, the levels of BCG-specific T lymphocytes peak 10 weeks after vaccination [23]. The levels of Mtb-specific IFN-γ-secreting T cells declined in both TB and LTBI patients during anti-TB treatment, suggesting that the IGRA results reflect the mycobacterial load [24,25]. In the present study, the QFT-G test values fell over the 5-year interval in most QFT-G-positive subjects (90.9%), and almost half became negative (54.5%). However, when the earlier results were compared with recent study QFT-GIT data, 10 of 38 (26.3%) previously negative subjects were of intermediate status and 1 (2.6%) was positive; this positive case was negative upon recent QFT-G testing. These data thus also suggested that the sensitivities of the two types of test differed, and that QFT-GIT testing was superior in terms of sensitivity. However, the results of the two tests conducted on the same subjects tended to differ, with statistical significance, suggesting that data from either test should not be compared.

Our present results using the QFT-G test are similar to those of a previous work with HCW of a Japanese tuberculosis referral hospital; approximately 10% were positive [26]. However, use of the more sensitive QFT-GIT test in the present study diagnosed 25% of subjects with LTBI; this proportion is very much higher than that of the general population [22]. A recent systematic review of the utility of IGRA assays used to screen HCW for TB showed that the initial positivity rate was 1.3-31.0%; the analysis included data from countries where the incidence of TB is high [7]. Such variation is attributable to differences in sample sizes and the backgrounds of HCW among the studies; the extent of involvement and contact with TB patients, administration of chemotherapy, and years of work with TB patients, will have varied significantly among the studies.

In conclusion, our simultaneous and longitudinal study of the same HCW including medical staff in TB-specific wards in a hospital in Japan suggests that QFT-GIT should be used for the screening of Mtb infection in HCW in Japan.

**Acknowledgements**

This work was supported in part by a Grant-in-Aid for Scientific Research (C)
from the Japan Society for the Promotion of Science to Koichi Suzuki and Yoshihiko Hoshino and a grant-in-aid from the Ministry of Health, Labor and Welfare of Japan (H21-Shinkou-Ippan-008 and H24-Shinkou-Ippan-010) to Tomoshige Matsumoto.

References

1. Ohsbori M, Hoshino Y, Yamauchi Y, Uchimura K (2007) [Current epidemiological situation of tuberculosis in the workplace: considering the risk of tuberculosis among nurses]. Kekkaku 82: 85-93.
2. Yoshihama T, Harada N, Higuchi K, Nakajima Y, Ogata H (2009) Estimation of incidence of tuberculosis infection in health-care workers using repeated interferon-gamma assays. Epidemiol Infect 137: 1691-1698.
3. Jarvis WR (1993) Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. Res Microbiol 144: 117-122.
4. Jerer JA, Klevens RM, Privett TD, Smith PJ, Crawford JT, et al. (1995) Tuberculosis in health care workers at a hospital with an outbreak of multidrug-resistant Mycobacterium tuberculosis. Arch Intern Med 155: 854-859.
5. Usui T, Yamanaka K, Nomura H, Tokudome S (2000) Elevated risk of tuberculosis by occupation with special reference to health care workers. J Epidemiol 10: 1-6.
6. Jo KW, Hong Y, Park JS, Bae IG, Eom JS, et al. (2013) Prevalence of Latent Tuberculosis Infection among Health Care Workers in South Korea: A Multicenter Study. Tuberc Respir Dis (Seoul) 75: 18-24.
7. Ringshausen FC, Nienhaus A, Schablon A, Schlösser S, Schultze-Werninghaus G, et al. (2010) Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis 10: 220.
8. Schablon A, Harling M, DIel R, Nienhaus A (2010) Risk of latent TB infection in individuals employed in the healthcare sector in Germany: a multicentre prevalence study. BMC Infect Dis 10: 107.
9. Hotta K, Ogura T, Nishii K, Kodani T, Onishi M, et al. (2007) Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students. PLoS One 2: e803.
10. Denkinger CM, Dheka K, Pai M (2011) Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion? Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 17: 806-814.
11. Pai M, Riley LW, Colford JM Jr (2004) Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4: 761-776.
12. Arend SM, Andersen P, van Meijgaarden KE, Skjøt RL, Subronto YW, et al. (2000) Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis 181: 1850-1854.
13. Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, et al. (2000) Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun 68: 3314-3321.
14. Aagaard C, Brock I, Olsen A, Ottenhoff TH, Weldingh K, et al. (2004) Mapping immune reactivity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. J Infect Dis 189: 812-819.
15. Higuchi K, Kawabe Y, Mitalai S, Yoshiyama T, Harada N, et al. (2009) Comparison of performance in two diagnostic methods for tuberculosis infection. Med Microbiol Immunol 198: 33-37.
16. Higuchi K, Sekiya Y, Igar H, Watanabe A, Harada N (2012) Comparison of specificities between two interferon-gamma release assays in Japan. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 16: 1190-1192.
17. Prevention Committee of the Japanese Society for Tuberculosis (2013) Guidelines for using QuantiFERON TB Gold in-tube. Kekkaku 88: 33-37.
18. Ariga H, Nagai H, Kurashima A, Hoshino Y, Shoji S, et al. (2011) Stratified Threshold Values of QuantiFERON Assay for Diagnosing Tuberculosis Infection in Immunocompromised Populations. Tuberc Res Treat 2011: 940642.
19. Committees for the Tuberculosis Prevention of the Japanese Society for Tuberculosis (2011) [Practice guidelines for usage of QuantiFERON TB-2G test]. Kekkaku 86: 839-844.
20. Harada N, Higuchi K, Yoshiyama T, Kawabe Y, Fujita A, et al. (2008) Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect Dis 56: 348-353.
21. Mahomed H, Hughes EE, Hawkridge T, Minnies D, Simon E, et al. (2006) Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection. Int J Tuberc Lung Dis 10: 310-316.
22. Mori T, Harada N, Higuchi K, Sekiya Y, Uchimura K, et al. (2007) Waning of the specific interferon-gamma response after years of tuberculosis infection. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 11: 1021-1025.
23. Soares AP, Kwong Chung CK, Choice T, Hughes EE, Jacobs G, et al. (2013) Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis 207: 1084-1094.
24. Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, et al. (2001) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183: 469-477.
25. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, et al. (2006) Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 174: 831-839.
26. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, et al. (2006) Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America 27: 442-448.

Submit your next manuscript and get advantages of OMICS

Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 300 Open Access Journals
- 25,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, & B&G, Index Copernicus and Google Scholar etc
- Sharing Option, Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission